4D Molecular Therapeutics, Inc. is a pharmaceutical company based in the United States of America. With a Risk Rating Score of 27.4, the company is considered to be at a medium risk level. Specializing in gene therapy, 4D Molecular Therapeutics focuses on developing product candidates using targeted and evolved AAV vectors in the areas of Ophthalmology, Cardiology, and Pulmonology. Their innovative approach and portfolio of gene therapy products make them a key player in the industry.